Background: Subcutaneous methylnaltrexone, a peripherally acting l-opioid receptor antagonist, improves opioid-induced constipation (OIC) in patients with chronic noncancer pain. An oral methylnaltrexone formulation has been developed. Methods: In this phase 3, double-blind trial, adults with chronic noncancer pain receiving opioid doses of ≥ 50 mg/ day oral morphine equivalents with OIC were randomly assigned to oral methylnaltrexone (150, 300, or 450 mg) or placebo once daily (QD) for 4 weeks followed by as-needed dosing for 8 weeks. Patients who had ≥ 3 rescue-free bowel movements (RFBMs)/week, with an increase of ≥ 1 RFBM/ week from baseline for ≥ 3 of 4 weeks during the QD period, were responders. Results: Overall, 803 patients were included in the analyses. A significantly greater percentage of patients had an increase in mean percentage of dosing days resulting in an RFBM within 4 hours of dosing during weeks 1 through 4 (QD period; primary endpoint) with methylnaltrexone (300 mg/ day [24.6%; P = 0.002] and 450 mg/day [27.4%; P < 0.0001]) vs. placebo (18.2%). The percentage of responders (49.3% for 300 mg [P = 0.03] and 51.5% for 450 mg [P = 0.005] vs. 38.3% with placebo) and change from baseline in mean number of weekly RFBMs (difference vs. placebo, 0.5 for 300 mg [P = 0.03] and 0.5 for 450 mg [P = 0.02]) was significantly greater with methylnaltrexone 300 and 450 mg/day vs. placebo during the QD period. All dosages of oral methylnaltrexone were well tolerated. Conclusions: Oral methylnaltrexone was efficacious and well tolerated for OIC in patients with chronic noncancer pain, particularly the 450-mg dose. &
INTRODUCTION
Opioid analgesics are often administered to treat patients with moderate-to-severe noncancer pain (eg, osteoarthritis). 1 However, opioids bind d, j, and l receptors in the gastrointestinal (GI) tract 1 and may impact GI function. For example, the activation of l-opioid receptors slows GI motility, inhibiting forward peristalsis by interfering with synchronized smooth muscle contraction in the small intestines and colon, 2 and leads to constipation. Indeed, constipation is reported to be the most common and bothersome symptom for patients receiving opioid therapy 3, 4 and may cause patients to reduce the dose or discontinue opioid use, [5] [6] [7] [8] [9] potentially leading to incomplete pain relief. Unfortunately, in contrast with other opioidinduced GI-related adverse effects (eg, nausea), tolerance to opioid-induced constipation (OIC) develops very slowly or not at all. 10 Stool softeners and laxatives are often used for the relief of OIC because of their low cost and easy availability, 11 but they do not influence the specific mechanisms that underlie the disorder, and wellcontrolled studies with over-the-counter laxatives are lacking.
Methylnaltrexone (Relistor â , Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, U.S.A.) is a l-opioid receptor antagonist that improves GI transit without affecting l-opioid receptor-associated analgesia. [12] [13] [14] A subcutaneous formulation of methylnaltrexone has been shown to be efficacious and well tolerated for the treatment of OIC in patients with chronic noncancer pain 15, 16 and in patients with advanced illness who are receiving palliative care. [17] [18] [19] [20] Given the need for the long-term management of OIC and the potential benefit of other available options for methylnaltrexone administration, an oral formulation of methylnaltrexone was approved by the U.S. Food and Drug Administration in July 2016. This study evaluated the efficacy and safety of oral methylnaltrexone in patients with chronic noncancer pain and OIC.
METHODS

Study Population
Individuals ≥ 18 years of age with a history of OIC (≥ 30 days) who had chronic nonmalignant pain for ≥ 2 months and were receiving ≥ 50 mg/day of oral morphine equivalent doses (MEDs) for ≥ 14 days were eligible for participation in the screening period of the trial. Opioid-induced constipation was confirmed during the 14 AE 2 day screening period and defined as having < 3 rescue-free bowel movements (RFBMs) per week that were associated with ≥ 1 of the following: ≥ 25% of RFBMs categorized as type 1 or type 2 on the Bristol Stool Form Scale; straining during ≥ 25% of RFBMs or ≥ 25% of RFBMs with a sensation of incomplete evacuation.
Patients with a history of mechanical bowel obstruction or megacolon, clinically significant GI disorders (eg, fecal incontinence, inflammatory bowel disease), those who had rectal bleeding not associated with hemorrhoids or fissure within 60 days of screening, and those who had planned surgery during the study were excluded. Use of prokinetic agents, stool softeners, 5-HT 3 receptor antagonists, lubiprostone, tegaserod, loperamide, partial opioid agonists, or a combination of opioid agonists or antagonists was not permitted.
Study Design
This phase 3, randomized, placebo-controlled, doubleblind trial was conducted at 117 sites in the United States between September 2010 and November 2011 (ClinicalTrials.gov identifier: NCT01186770). The study consisted of a 14-day screening period, a 28-day (4-week) period during which patients received treatment once daily (QD), a 56-day (8-week) period during which patients administered treatment as needed (PRN), and a 14-day follow-up period. Patients and investigators remained blinded to treatment through the end of the study. The study was approved by the appropriate institutional review boards and conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.
Study Medication
Eligible patients with confirmed OIC during the screening period were randomly assigned in a 1:1:1:1 ratio using a computer-generated randomization schedule to receive oral methylnaltrexone 150, 300, or 450 mg/day or placebo QD for 4 weeks. During the 8-week PRN period, patients continued to receive the same treatment to which they were assigned at randomization (QD period). Laxative therapy was discontinued at the screening visit; however, rescue laxative therapy (ie, up to three oral bisacodyl tablets per day) was permitted for patients who did not have a bowel movement for 3 consecutive study days. If bisacodyl tablets did not result in a bowel movement within 24 hours, an enema or an additional dose of bisacodyl tablets was permitted.
Study Assessments
The primary efficacy endpoint of the study was the mean percentage of dosing days that resulted in an RFBM within 4 hours of dosing during weeks 1 to 4 (QD period). Key secondary efficacy endpoints included the following: (1) percentage of responders (ie, had ≥ 3 RFBMs/week, with an increase of ≥ 1 RFBM/week from baseline for at least 3 of the 4 weeks) during weeks 1 to 4 (QD period) and (2) the change in weekly number of RFBMs from baseline during weeks 1 to 4 (QD period). Additional efficacy endpoints included the percentage of patients who were overall responders (ie, responders for ≥ 9 of 12 weeks), percentage of methylnaltrexone doses that resulted in an RFBM within 4 hours after the first dose, time to the first RFBM after the first dose, the percentage of patients who had ≥ 3 RFBMs per week and an increase of at least 1 RFBM per week above baseline, the percentage of patients who had ≥ 3 RFBMs per week, and the percentage of patients who had an increase of ≥ 1 weekly RFBM from baseline. Key safety assessments included use of a rescue laxative and average pain score during the QD and PRN periods.
Patients reported the time of all bowel movements and rescue laxative use daily via telephone using an interactive voice response system. Pain intensity during the previous 24 hours was assessed using the Numerical Rating of Pain Intensity Scale that ranged from 0 (none) to 10 (worst pain possible) at all study visits (baseline and days 14, 28, 42, 56, and 84). Vital signs and adverse events (AEs) were monitored throughout the study, and an electrocardiogram was performed at screening and on day 28.
Statistical Analyses
Assuming that 20% of dosing days would result in an RFBM within 4 hours of dosing during the first 4 weeks of the study among patients who received placebo, a power of ≥ 90%, and a two-tailed alpha level of 0.017, it was estimated that 700 patients would be necessary to detect a minimum treatment difference between any methylnaltrexone dose and placebo of 20%. All patients who received ≥ 1 dose of the study drug were included in the intent-to-treat (ITT) population.
The prespecified analyses of the efficacy endpoints were adjusted for multiplicity with regard to multiple dose comparisons and ordered endpoints. Betweengroup differences in the primary endpoint (ie, mean percentage of dosing days that resulted in an RFBM within 4 hours of dosing during the QD period) were analyzed in the ITT population using an analysis of covariance model (ANCOVA) with the randomized dose group as a fixed effect and the study center as a covariate. Analyses of responders and overall responders were based on a logistic regression model with treatment as an effect and geographic region as a covariate. During the QD period, the change in weekly number of RFBMs from baseline was analyzed using an ANCOVA model with treatment as an effect and geographic region and baseline values as covariates. Time-to-event endpoints were estimated using the Kaplan-Meier method and compared using the log-rank test stratified by center; sensitivity analyses were also performed (eg, worst-case scenarios). For the primary endpoint, missing values were not carried forward (ie, a worst-case method). The key secondary endpoint of percentage of responders was analyzed using a worst-case method and a last observation carried forward (LOCF) analysis in which the last nonmissing 4 days with diary data were imputed for the week with < 4 diary days. Change in weekly number of RFBMs from baseline during the first 4 weeks was analyzed using observed-case scenarios. In the worst-case analyses for responder endpoints, missing data were considered a nonresponse for that week. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 13.0. Demographics, baseline characteristics, and safety data were summarized using descriptive statistics.
RESULTS
Study Population
Of the 804 patients enrolled in the study, 803 received ≥ 1 dose of the study medication during the QD period and were included in the ITT population (Figure 1 ). Most patients (83.1% to 90.0%) continued into the 8-week PRN period. The most common reasons for discontinuation (ie, not continuing into the 8-week PRN period) among patients in the methylnaltrexone groups were patient request (3.0% to 4.0%), loss to follow-up (0.5% to 3.5%), and AEs (0.5% to 3.0%; see Figure 1 ). Most patients who entered the PRN period completed the study (85.6% to 90.4%), with similar percentages completing among treatment groups (see Figure 1) . No major differences existed in baseline demographic or disease characteristics among treatment groups (Table 1) . Most patients were women (56.7% to 66.2%) and the mean age ranged from 50.9 to 52.6 years. In all treatment groups (65.7% to 72.1%), back pain was the predominant pain condition. During the QD and PRN periods, mean days of exposure to methylnaltrexone (groups combined) was 26.1 and 50.0 days, respectively. The mean number of doses per week administered during the QD and PRN periods was generally similar between placebo and methylnaltrexone groups: for example, at week 4 of the QD period, placebo vs. methylnaltrexone groups, the rates were 6.1 vs. 6.3 to 6.5; at week 12 of PRN period, they were 4.5 vs. 4.3 to 4.6).
Efficacy
A significantly greater percentage of patients in the oral methylnaltrexone 300 mg/day (24.6%; P = 0.002) and 450 mg/day (27.4%; P < 0.0001) groups met the primary endpoint (ie, mean percentage of dosing days that resulted in an RFBM within 4 hours of dosing during weeks 1 to 4 [QD period]) compared with placebo (18.2%). Effects appeared linearly related to methylnaltrexone dose. In addition, statistically significant differences in methylnaltrexone 300 and 450 mg/ day groups were observed as early as week 1 and were generally maintained throughout the study (Figure 2) .
During the QD period, the percentage of responders was statistically significantly greater in the methylnaltrexone 300 and 450 mg/day groups compared with placebo (worst-case analysis; Figure 3A) . Similar results were observed with the LOCF analyses (300 mg, 51.7%; 450 mg, 54.5% vs. placebo, 40.8%; P = 0.03 for 300 mg and P = 0.004 for 450 mg). In the methylnaltrexone 450 mg/day group, the percentage of overall responders was significant compared with placebo, in both worst-case ( Figure 3B ) and LOCF analyses (450 mg, 51.0% vs. placebo, 35.8%; P = 0.002). Throughout the QD period for methylnaltrexone, change from baseline in the mean number of weekly RFBMs was significantly greater for 300 and 450 mg/day (both 2.4; P = 0.03 for 300 mg/day and P = 0.02 for 450 mg/day) compared with placebo (1.9), but not for methylnaltrexone 150 mg/day (2.0 with 150 mg/day vs. 1.9 with placebo; P = 0.7). 
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The time to achieving a first RFBM was significantly shorter for all methylnaltrexone groups compared with placebo (P < 0.05 for all dose groups; Figure 4 ) throughout a 24-hour period. A significantly greater percentage of patients receiving methylnaltrexone 300 mg (25.4%; P < 0.0001) and 450 mg (23.5%; P < 0.0001) had an RFBM within 4 hours of the first dose compared with placebo (8%). At the end of the QD period, a mean of 24.3% and 26.2% of doses in the methylnaltrexone 300-and 450-mg groups, respectively, resulted in an RFBM within 4 hours, compared with 19.2% with placebo (P ≤ 0.05 for both). Similar results were observed at the end of the PRN period (methylnaltrexone 300 mg, 27.6%; methylnaltrexone 450 mg, 30.5%; placebo, 18.5%; P ≤ 0.01 for each vs. placebo).
The percentage of total study days during which patients took rescue laxatives was higher with placebo (6.2%) compared with any dose of methylnaltrexone (150 mg, 5.8%; 300 mg, 5.1%; 450 mg, 4.3%), and the methylnaltrexone 450-mg group showed statistically significant differences compared with the placebo group (P = 0.024). In addition, patients who received methylnaltrexone 450 mg had approximately 30% fewer days of rescue laxative use compared with those who received placebo.
Safety
All dosages of methylnaltrexone were well tolerated during the QD and PRN periods (Table 2) . Overall, during the 12 weeks of the study, the most common AEs in the methylnaltrexone 450-mg group (n = 200) were abdominal pain (10.5% vs. 8.5% with placebo; eg, cramping), nausea (6.0% vs. 9.0% with placebo), and diarrhea (8.0% vs. 3.5% with placebo . Discontinuations because of AEs of severe intensity were reported in four (2.0%) patients in the placebo group, one (0.5%) patient in the methylnaltrexone 150-mg group, five (2.5%) patients in the methylnaltrexone 300-mg group, and 0 patients in the methylnaltrexone 450-mg group. Among these 10 patients who discontinued because of a severe AE, each type of AE event experienced was unique, with no two patients experiencing the same AE in a particular treatment group. The incidence of serious AEs (SAEs) was similar with methylnaltrexone (3%; pooled) and placebo (4%), and all resolved. The most common SAEs were noncardiac chest pain (placebo, n = 2), suicidal ideation (methylnaltrexone 150 mg, n = 1; 300 mg, n = 1), and dyspnea (placebo, n = 2; methylnaltrexone 150 mg, n = 1).
No statistically significant differences in mean changes from baseline in pain score at weeks 4 or 12 were seen between the placebo group and the three methylnaltrexone groups. Also, no clinically meaningful changes in clinical laboratory parameters or electrocardiographic findings were found for any methylnaltrexone dose group vs. placebo during the study. No deaths or major adverse cardiovascular events were reported during the 12-week study.
DISCUSSION
Constipation related to the slowing of GI transit during opioid treatment can be a substantial burden for patients and may lead to inadequate pain relief because of patient nonadherence. [5] [6] [7] [8] Thus, medications that improve GI motility in the presence of opioids while not interfering with opioid analgesia are critical for patients who are prescribed long-term opioid therapy. In this 12-week, randomized, double-blind, placebo-controlled trial, an oral form of methylnaltrexone, a l-opioid receptor antagonist, provided clinically significant, dose-related improvements in OIC compared with placebo in patients with chronic noncancer pain. No significant reductions in opioid analgesia were observed, and oral methylnaltrexone was well tolerated. The efficacy of oral methylnaltrexone observed in the current study is consistent with results from a phase 3 trial of a subcutaneous methylnaltrexone for the treatment of OIC in patients with chronic noncancer pain that included a 4-week double-blind phase followed by an 8-week open-label extension. 15 In that phase 3 trial, subcutaneous injection of methylnaltrexone 12 mg QD in patients with OIC and noncancer pain for 4 weeks resulted in a significantly shorter time to a first bowel movement compared with placebo (P < 0.001). A similar efficacy profile was observed with the oral methylnaltrexone formulation in the current study (ie, time to the achievement of a first RFBM was significantly shorter for all methylnaltrexone groups compared with placebo; P < 0.05 for all oral methylnaltrexone groups [150, 300, and 450 mg]). In addition, during the double-blind phase of the study of subcutaneous methylnaltrexone, a significantly greater percentage of patients who received methylnaltrexone QD or every other day had an RFBM within the first 4 hours after the first dose vs. placebo (34.2% vs. 9.9%; P < 0.001). 15 Similarly in our study, statistically significant differences were observed with oral methylnaltrexone 300 mg (25.4%; P < 0.0001) and 450 mg (23.5%; P < 0.0001) vs. placebo (8.0%), although the overall percentage of patients who had an RFBM within the first 4 hours was lower with oral methylnaltrexone (up to 20.6%) than that observed with the subcutaneous formulation (34.2%), perhaps because of the time required for oral absorption. Finally, in the subcutaneous formulation study, patients who received placebo during the double-blind period of the trial who switched 16 In our study, the efficacy of oral methylnaltrexone was also maintained throughout the 12-week study period, with the percentage of overall responders being significantly greater with methylnaltrexone 450 mg compared with placebo.
The overall tolerability profile of oral methylnaltrexone was favorable, with no new safety signals observed as compared with the data reported for the subcutaneous formulation in patients with chronic noncancer pain. 15 Consistent with the subcutaneous methylnaltrexone formulation, 21 the oral methylnaltrexone formulation had no apparent impact on opioid analgesia and no apparent cardiac-related safety signals. The most common treatment-emergent AEs with both formulations were GI-related events (eg, abdominal pain, nausea). However, the incidence of GI-related AEs with oral methylnaltrexone was similar to that associated with placebo, whereas GI events (except for vomiting) were more common with subcutaneous methylnaltrexone than with placebo. 15 In conclusion, an oral formulation of methylnaltrexone was efficacious and well tolerated for treating OIC in patients with chronic noncancer pain, particularly the 450-mg dose. Response was durable over a 12-week period, including when administered for 8 weeks PRN. Given its efficaciousness and tolerability profile, oral methylnaltrexone offers an alternative to subcutaneous methylnaltrexone for patients with noncancer pain and OIC.
